Similar efficacy outcomes with peripheral blood stem cell versus bone marrow for autologous stem cell transplantation in acute myeloid leukemia: Long-term follow-up of the EORTC-GIMEMA randomized AML-10 trial.
Fréderic BaronFabio EfficaceLaura CannellaMarian Stevens-KroefSergio AmadoriTheo de WitteMichael LübbertAdriano VendittiStefan SuciuPublished in: American journal of hematology (2024)
We report here the long-term follow-up of the only prospective randomized trial of autologous hematopoietic stem cell transplantation (auto-HSCT) with peripheral blood stem cells (APBSCT) versus auto-HSCT with bone marrow (ABMT) in acute myeloid leukemia (AML) patients in first remission (CR). We observed that among patients alive and still in CR 5 years after planned auto-HSCT, approximately 10% of the patients died in the following 10 years. This stresses the need for long-term close surveillance of AML patients after auto-HSCT. Further, long-term follow-up of the trial confirms that APBSCT was comparable to ABMT in term of disease-free-survival and overall survival.
Keyphrases
- stem cells
- bone marrow
- end stage renal disease
- peripheral blood
- stem cell transplantation
- chronic kidney disease
- ejection fraction
- acute myeloid leukemia
- newly diagnosed
- clinical trial
- prognostic factors
- free survival
- peritoneal dialysis
- randomized controlled trial
- mesenchymal stem cells
- phase iii
- public health
- type diabetes
- cell therapy
- phase ii
- preterm infants
- double blind
- gestational age
- glycemic control